Farxiga (dapagliflozin) and Jardiance (empagliflozin) are prescription medications that are commonly used for type 2 diabetes ...
It says Farxiga will reach peak sales of $9 billion in 2028, with Jardiance forecast to reach $4.6 billion, assuming a launch for HFrEF this year. The bulk of those sales will come from HFpEF ...
The FDA has approved AstraZeneca’s SGLT2 inhibitor Farxiga as a treatment candidate for all patients with heart failure, putting the drug back in contention with rival Jardiance from Boehringer ...